MedPath

Roche Holding AG

Roche Holding AG logo
🇨🇭Switzerland
Ownership
Public
Established
1896-01-15
Employees
103.6K
Market Cap
$270.5B
Website
http://www.roche.com

A Study of Avastin (Bevacizumab) Combined With Chemotherapy in Patients With Metastatic Cancer of the Colon or Rectum

Phase 2
Completed
Conditions
Colorectal Cancer
Interventions
First Posted Date
2010-08-13
Last Posted Date
2014-07-28
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
54
Registration Number
NCT01181609

A Study of 48 Versus 96 Weeks of Peginterferon Alfa-2a [Pegasys] Treatment, With or Without Entecavir, in Patients With Chronic Hepatitis B.

Phase 4
Withdrawn
Conditions
Hepatitis B, Chronic
Interventions
Drug: peginterferon alfa-2a [Pegasys]
Drug: entecavir
Drug: placebo
First Posted Date
2010-08-11
Last Posted Date
2017-02-17
Lead Sponsor
Hoffmann-La Roche
Registration Number
NCT01179594

A Study on Rituximab (MabThera) in Participants With Chronic Lymphocytic Leukemia (CLL)

Completed
Conditions
Lymphocytic Leukemia, Chronic
Interventions
First Posted Date
2010-08-09
Last Posted Date
2018-10-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
681
Registration Number
NCT01178086
Locations
🇩🇪

PIOH PD Dr. R. Schnell - Dr. H. Schulz - Dr. M. Hellmann, Frechen, Germany

A Study on the Correlation Between Tarceva (Erlotinib) - Induced Rash and Efficacy in EGFR Mutated Participants With Advanced Non-Small Cell Lung Cancer Receiving First-Line Therapy

Phase 2
Completed
Conditions
Non-Squamous Non-Small Cell Lung Cancer
Interventions
First Posted Date
2010-08-03
Last Posted Date
2018-09-17
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
60
Registration Number
NCT01174563
Locations
🇮🇱

Haemek Hospital; Oncology, Afula, Israel

🇮🇱

Barzilai; Oncology, Ashkelon, Israel

🇮🇱

Meir Medical Center; Oncology, Kfar-Saba, Israel

and more 13 locations

A Pharmacokinetic Study on Co-administration of Tamiflu (Oseltamivir) and Rimantadine in Healthy Volunteers

Phase 1
Completed
Conditions
Healthy Volunteer
Interventions
First Posted Date
2010-07-30
Last Posted Date
2016-08-19
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
24
Registration Number
NCT01172847

A Study of Bevacizumab (Avastin) in Combination With Chemotherapy in Participants With Metastatic Cancer of the Colon or Rectum.

Phase 3
Completed
Conditions
Colorectal Cancer
Interventions
Drug: Bevacizumab
Drug: Fluoropyrimidine-based Chemotherapy
First Posted Date
2010-07-26
Last Posted Date
2016-12-08
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
168
Registration Number
NCT01169558

An Observational Study of NeoRecormon (Epoetin Beta) in Cancer Patients With Anemia (FAST)

Completed
Conditions
Anemia, Neoplasms
Interventions
Drug: epoetin beta [NeoRecormon]
First Posted Date
2010-07-23
Last Posted Date
2015-10-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
1060
Registration Number
NCT01168349

A Study on the Pharmacokinetics and Safety of Valcyte (Valganciclovir) in Pediatric Heart Transplant Recipients Less Than 4 Months of Age

Phase 1
Completed
Conditions
Cytomegalovirus Infections, Heart Transplantation
Interventions
First Posted Date
2010-07-20
Last Posted Date
2016-11-02
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
17
Registration Number
NCT01165580

A Pharmacokinetic and Metabolism Study of 14C-labeled RO5185426 on Patients With Metastatic Melanoma

Phase 1
Completed
Conditions
Malignant Melanoma
Interventions
Drug: RO5185426
First Posted Date
2010-07-19
Last Posted Date
2023-04-05
Lead Sponsor
Hoffmann-La Roche
Target Recruit Count
7
Registration Number
NCT01164891
© Copyright 2025. All Rights Reserved by MedPath